Ensign Peak Advisors’s Myriad Genetics MYGN Stock Holding History

Ensign Peak Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,356	Closed	-$33.1K	–	1739
2026 Q1	$33.1K	Hold	7,356	–	–	﹤0.01%	1697
2025 Q4	$45.2K	Sell	7,356 -13,950	-65%	-$101K	﹤0.01%	1670
2025 Q3	$154K	Sell	21,306 -10,300	-33%	-$61.2K	﹤0.01%	1669
2025 Q2	$168K	Hold	31,606	–	–	﹤0.01%	1684
2025 Q1	$280K	Hold	31,606	–	–	﹤0.01%	1648
2024 Q4	$433K	Hold	31,606	–	–	﹤0.01%	1632
2024 Q3	$866K	Hold	31,606	–	–	﹤0.01%	1406
2024 Q2	$773K	Hold	31,606	–	–	﹤0.01%	1443
2024 Q1	$674K	Sell	31,606 -1,594	-5%	-$34.3K	﹤0.01%	1544
2023 Q4	$635K	Buy	33,200 +16,850	+103%	+$292K	﹤0.01%	1603
2023 Q3	$262K	Hold	16,350	–	–	﹤0.01%	1708
2023 Q2	$379K	Buy	+16,350	New	+$357K	﹤0.01%	1689
2022 Q4	–	Sell	-28,188	Closed	-$538K	–	2068
2022 Q3	$538K	Hold	28,188	–	–	﹤0.01%	1416
2022 Q2	$512K	Hold	28,188	–	–	﹤0.01%	1448
2022 Q1	$710K	Hold	28,188	–	–	﹤0.01%	1394
2021 Q4	$778K	Sell	28,188 -34,610	-55%	-$1M	﹤0.01%	1407
2021 Q3	$2.03M	Hold	62,798	–	–	﹤0.01%	1115
2021 Q2	$1.92M	Hold	62,798	–	–	﹤0.01%	1154
2021 Q1	$1.91M	Hold	62,798	–	–	﹤0.01%	1136
2020 Q4	$1.24M	Hold	62,798	–	–	﹤0.01%	1307
2020 Q3	$819K	Hold	62,798	–	–	﹤0.01%	1394
2020 Q2	$712K	Hold	62,798	–	–	﹤0.01%	1388
2020 Q1	$899K	Buy	62,798 +5,700	+10%	+$120K	﹤0.01%	1208
2019 Q4	$1.55M	Buy	+57,098	New	+$1.57M	﹤0.01%	1165

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's MYGN Position: Q2 2026 in Review

Ensign Peak Advisors sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 7,356 shares — an estimated $33.1K sold.

Ensign Peak Advisors first reported a position in MYGN in Q4 2019 and held it in 24 quarters. The position peaked at $2.03M in Q3 2021. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Ensign Peak Advisors reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
Ensign Peak Advisors sold 7,356 Myriad Genetics shares in Q2 2026, an estimated $33.1K.
Ensign Peak Advisors first reported a position in Myriad Genetics in Q4 2019 and held it in 24 quarters.
Ensign Peak Advisors's Myriad Genetics position peaked at $2.03M in Q3 2021.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.